Friendly races can spur scientists to innovate better and faster, but experts in public health, biotech and national security see many ways today’s vaccine nationalism might backfire. Patriotic competitions, however, have dark sides. Warp Speed is pouring billions into vaccine candidates around the world, except in China. Meanwhile in the U.S., months out from a presidential election, Trump is relying on the government’s Operation Warp Speed to deliver a Covid-19 vaccine by January 2021-a feat that “will be one of the greatest scientific and humanitarian accomplishments in history,” according to the administration. “For China, it would be awesome to be first,” says Carafano, even if the benefits are ephemeral-so much so that Chinese hackers have, according to the FBI, been attempting to steal U.S. Of the 10 vaccines currently in clinical trials globally, five are from China, according to the World Health Organization.
#Race into space money cheat full
as the world leader in biotech and has put the full weight of the state behind the country’s vaccine candidates.
Today, eyes are on the not-quite-cold-war rivalry between China and the United States, who have been trading blame for the current pandemic.
It’s hard not to feel that their discovery … was the result of the special training that they received in that country, the special resources that they were able to access in that country.” “It’s an incredible coup to have somebody in your country develop something that has such incredible global significance. “This national-type race is something that has been around for maybe 200 years at least,” says Naomi Rogers, a history of medicine professor at Yale University. As coronavirus cases mount around the world and economies continue to limp through lockdowns, nations are not just competing for first access to the vaccine, they’re also hoping to claim victory in a race that would affirm their national identities, resourcefulness and power-proving that their character, systems and intellect are superior. Others see parallels to the dash to invent a marketable light bulb-an American discovery that stunned Europe and put the United States on the map as a center of innovation. Some think the contest recalls the antagonistic days of the Cold War-“a sputnik moment,” says biotech investor Brad Loncar. President Donald Trump speaks in the Rose Garden of the White House on May 29, 2020. could get first access to a vaccine produced by French pharma giant Sanofi, President Emmanuel Macron announced that Sanofi would be dramatically ramping up operations in France to put “Sanofi and France at the heart of excellence in the fight … to find a vaccine.” Invoking the “genius of Louis Pasteur,” Marcon hailed France as “a great vaccine country.”
#Race into space money cheat tv
“If China is the first to develop this weapon with its own intellectual property rights, it will demonstrate not only the progress of Chinese science and technology, but also our image as a major power,” she said on state TV in March. In China, where a vaccine victory could turn a country that started the virus’ spread into the savior of the world, the virologist and major general leading the country’s vaccine project has been hailed as a “goddess” on social media. Below: The CureVac headquarters in Tubingen, Germany.ĪP Photo/Markus Schreiber, Pool Matthias Hangst/Getty Images Top: CureVac main shareholder Dietmar Hopp, left, and CureVac CEO Franz-Werner Haas, right, during a news conference with German Economy Minister Peter Altmaier on June 15, 2020. Public health experts say we should be worried. While scientists try to collaborate across national boundaries, national leaders are caught up in an old-fashioned game of one-upmanship-a competition that is driving, and in some cases complicating, the most consequential medical challenge of the 21st century. The strange fate of CureVac shows just how much national pride is defining the lines of the global race for the Covid-19 vaccine. “Betting on one horse,” he says, is a mistake.
Piontek, whose biotech firm is also developing a Covid-19 vaccine, says Germany would have done better to invest in multiple companies with different approaches. Berlin,” set off outrage in the Bundestag, elicited cries of “Germany is not for sale!” and led the government to shell out 300 million euros for 23 percent of the firm-an unprecedented move. The offer, first reported in the German press under the headline “Trump vs. But, months earlier, the American president had insulted German pride by musing about paying CureVac to relocate to the United States.
0 kommentar(er)
